Competitors Within
Home-grown smaller players are giving biggies a run for their money in the US generics market.
Home-grown smaller players are giving biggies a run for their money in the US generics market.
Bengaluru-based Biocon’s portfolio of biologic drugs has grown rapidly in the last five years and the company wants it to be a $1 billion business by 2022.
Upper-middle-income households becoming the biggest demographic in 2030 will drive healthcare services.
India’s third-largest generic drugmaker Lupin is focussing on building a pipeline of specialty drugs, while cutting costs and addressing regulatory concerns.
Vinita Gupta is confident that new complex generics, specialty drugs and manufacturing quality enhancement plan will augur well for the company